Multiparametric MRI for prostate cancer detection: Performance in patients with prostate-specific antigen values between 2.5 and 10 ng/mL

Cooperberg, 2004, The changing face of low-risk prostate cancer: trends in clinical presentation and primary management, J Clin Oncol, 22, 2141, 10.1200/JCO.2004.10.062

Djavan, 2002, Repeat prostate biopsy: who, how and when? A review, Eur Urol, 42, 93, 10.1016/S0302-2838(02)00256-7

Thompson, 2004, Prevalence of prostate cancer among men with a prostate specific antigen level ≤4.0 ng per millilitre, N Engl J Med, 350, 2239, 10.1056/NEJMoa031918

Draisma, 2003, Lead times and over detection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer, J Natl Cancer Inst, 95, 868, 10.1093/jnci/95.12.868

Walsh, 2007, Clinical practice. Localized prostate cancer, N Engl J Med, 357, 2696, 10.1056/NEJMcp0706784

Zackrisson, 2004, The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable, J Urol, 17, 1500, 10.1097/01.ju.0000118052.59597.83

Klotz, 2010, Active surveillance for prostate cancer: patient selection and management, Curr Oncol, 17, 11, 10.3747/co.v17i0.713

Yu, 2000, Imaging prostate cancer, Radiol Clin North Am, 38, 59, 10.1016/S0033-8389(05)70150-0

Choi, 2007, Functional MR imaging of prostate cancer, Radiographics, 27, 63, 10.1148/rg.271065078

Sanders, 2013, Infection-related hospital admissions after transrectal biopsy of the prostate, ANZ J Surg, 83, 246, 10.1111/ans.12073

Utrera, 2011, Infectious complications after transrectal ultrasound-guided prostatic biopsy. Analysis of our experience, Arch Esp Urol, 64, 605

Dickinson, 2011, Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European Consensus Meeting, Eur Urol, 59, 477, 10.1016/j.eururo.2010.12.009

Kim, 2009, Multidisciplinary functional MR imaging for prostate cancer, Korean J Radiol, 10, 535, 10.3348/kjr.2009.10.6.535

Shukla-Dave, 2007, The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis, BJU, 99, 786, 10.1111/j.1464-410X.2007.06689.x

Lim, 2009, Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection-a multireader study, Radiology, 250, 145, 10.1148/radiol.2501080207

Akin, 2006, Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging, Radiology, 239, 784, 10.1148/radiol.2392050949

Kurhanewicz, 1996, Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution, Radiology, 198, 795, 10.1148/radiology.198.3.8628874

Perdona, 2011, Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection, Urol Oncol

Obuchowski, 2005, ROC analysis, AJR Am J Roentgenol, 184, 364, 10.2214/ajr.184.2.01840364

DeLong, 1988, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach, Biometrics, 44, 837, 10.2307/2531595

Schisterman, 2005, Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples, Epidemiology, 16, 73, 10.1097/01.ede.0000147512.81966.ba

Joseph, 2005, Statistical inference for proportions, AJR Am J Roentgenol, 184, 1057, 10.2214/ajr.184.4.01841057

Hawass, 1997, Comparing the sensitivities and specificities of two diagnostic procedures performed on the same group of patients, Br J Radiol, 70, 360, 10.1259/bjr.70.832.9166071

Dendukuri, 2005, Correlation and regression, AJR Am J Roentgenol, 185, 3, 10.2214/ajr.185.1.01850003

National Cancer Institute (NCI) http://www.cancer.gov/cancertopics/alphalist

Cirillo, 2008, Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours, Clin Radiol, 63, 871, 10.1016/j.crad.2007.10.020

Umbehr, 2009, Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis, Eur Urol, 55, 575, 10.1016/j.eururo.2008.10.019

Vilanova, 2007, Prostate cancer detection: magnetic resonance (MR) spectroscopy imaging, Abdom Imaging, 32, 253, 10.1007/s00261-007-9191-7

Westphalen, 2007, Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging, Radiology, 246, 177, 10.1148/radiol.2453062042

Carroll, 2006, Magnetic resonance imaging and spectroscopy of prostate cancer, Rev Urol, 8, 4

Zakian, 2005, Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy, Radiology, 234, 804, 10.1148/radiol.2343040363

Weinreb, 2009, Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study, Radiology, 251, 122, 10.1148/radiol.2511080409

Haider, 2007, Combined T2-weighted and diffusion weighted MRI for localization of prostate cancer, AJR Am J Roentgenol, 189, 323, 10.2214/AJR.07.2211

Tanimoto, 2007, Prostate cancer screening: the clinical value of diffusion weighted imaging and dynamic MR imaging in combination with T2-weighted imaging, J Magn Reson Imaging, 25, 146, 10.1002/jmri.20793

Woodfield, 2010, Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy, AJR Am J Roentgenol, 194, 316, 10.2214/AJR.09.2651

Franiel, 2011, Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding-multiparametric MR imaging for detection and biopsy planning, Radiology, 259, 162, 10.1148/radiol.10101251

Girometti, 2012, Negative predictive value for cancer in patients with “gray-zone” PSA level and prior negative biopsy: preliminary results with multiparametric 3.0 Tesla MR, J Magn Reson Imaging, 36, 943, 10.1002/jmri.23703

Tamada, 2011, Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/ml: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast enhanced MRI, and T2-weighted imaging, AJR Am J Roentgenol, 197, 664, 10.2214/AJR.10.5923

Kubota, 2008, The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer, Int J Urol, 15, 322, 10.1111/j.1442-2042.2008.01991.x

Kumar, 2007, Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.NMR, Biomed, 20, 11

Kumar, 2008, Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study, Urology, 72, 859, 10.1016/j.urology.2008.01.014

Vargas, 2012, Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study, Radiology, 265, 478, 10.1148/radiol.12120041

Futterer, 2006, Prostate cancer localization with dynamic contrast enhanced MR imaging and proton MR spectroscopic imaging, Radiology, 241, 449, 10.1148/radiol.2412051866

Petrie, 2000, Medical statistics at a glance, 138

Schulte, 2008, Utility of extended pattern prostate biopsies for tumor localization: pathologic correlations following radical prostatectomy, Cancer, 113, 1559, 10.1002/cncr.23781

Berglund, 2008, Pathological upgrading and upstaging with immediate repeat biopsy in patients eligible for active surveillance, J Urol, 180, 1964, 10.1016/j.juro.2008.07.051